Single-Arm PharmacoKinetic/PharmacoDynamic and Safety Study of Eryaspase (GRASPA) for Patients With Hypersensitivity to PEG-Asparaginase, Diagnosed With Ph(-) Acute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs ERY-ASP (Primary) ; Antineoplastics
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms NOR-GRASPALL 2016
- 11 Sep 2017 According to an ERYtech Pharma media release, first patients were recently enrolled in this study.
- 13 Apr 2017 Status changed from planning to recruiting.
- 11 Apr 2017 New trial record